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Abstract 
BACKGROUND: Immature teratoma is malignant ovarian germ cell tumours (MOGCTs). The case in pregnancy 
is very rare which less than 1% of all ovarian teratoma cases. The aim is to reach optimal and comprehensive 
management for immature ovarian teratoma in pregnancy to gain the healthiest maternal and fetal outcomes. 
CASE PRESENTATION: Thirty-one years old female G2P1A0, 8 weeks 1-day pregnancy, with left ovarian solid 
tumour 15 x 15 x 15 cm in size. At gestational age (GA) of 19 weeks 5 days, the size of the tumour was increasing 
rapidly to 30 x 30 x 30 cm. Alfa-fetoprotein raised to 699.9 IU/mL and LDH 579 U/L. The patient had gone primary 
conservative left oophorectomy, omentectomy, and ascites fluid cytology with histopathological conclusion grade 
II immature teratoma of left ovary containing the immature neuroepithelial and fat component: magnetic 
resonance imaging (MRI) at 25 weeks 3 days GA, no spreading. Amniocentesis performed at 27 weeks 2 days 
GA, the fetus had normal 46 chromosomes and sex XX without major structural abnormality. The patient had BEP 
chemotherapy start at 27 weeks 2 days GA. Patient in labour at 40 weeks 2 days GA. The female baby had 
spontaneous delivery with 2700 grams in body weight without congenital abnormality. Complete surgical staging 
performed at 58th days postpartum and histopathological result there was no malignant cell anymore, but post-
chemotherapy ovarian atrophy feature had found on the contralateral ovary. The patient showed psychosocial 
problem including post-chemotherapy depression and premature ovarian failure (POF). Immunohistochemistry 
(IHC) ER and PR of teratoma tissue showed immature component had ER (-) and PR (+). Follow up of the baby 
was in good condition.  
CONCLUSION: BEP chemotherapy become regimen choice for this case with fetal outcomes was good, but there 
was a POF sign on the mother. Survival of patient on this case is 62%, free recurrence survival post-BEP 84% 
and progressivity post complete surgical staging 8% without delay the chemotherapy. 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Malignant Ovarian Germ cell tumours 
(MOGCTs) is ovarian primordial cells origin, the most 
common is dysgerminoma, the second is immature 
teratoma, and the third is yolk sac tumour. The 
incidence of MOGCTs in pregnancy is very rare, 1 in 
12,500-25,000 of all pregnancy [1].
  
Immature teratoma is teratoma which 
contains embryonal neuroectodermal tissue 
component. The incidence of immature teratoma in 
pregnancy is considered as < 1% of all ovarian 
teratoma cases which occur in the first three decades 
of life and reproductive period. The incidence of 
immature teratoma in 2017 at Sanglah Hospital 
Denpasar – Bali was very rare, from 5 cases just 1 
case in pregnancy. 
The incidence of immature teratoma in 
pregnancy is very rare which cause a rare consensus 
about its management strategy. Pregnancy which 
occurs at the same time with immature teratoma type 
ovarian cancer will arise vice-versa effects both 
directly or indirectly for the pregnancy itself, fetus, and 
the progressivity of immature teratoma. The 
multidisciplinary approach involves oncologist, 
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pathologist, and perinatologist is needed for early 
diagnosis, definitive operation procedure, 
chemotherapy choice, management of delivery, 
perinatology management, long-term follow up of 
maternal and fetal chemotherapy effects, and the 
necessity of complete surgical staging relaparotomy 
and evaluation the possibility of metastasis. 
 
 
Case Illustration 
 
Thirty-one-year-old female, G2P1A0, 8 weeks 
1 day GA, with solid ovarian tumour 15 x 15 x 15 cm 
in size. At 19 weeks 5-day GA, the tumour size 
became 30 x 30 x 30 cm, solid, rough surface, mobile, 
and painful. Tumour marker was raising, AFP 699.9 
IU/mL and LDH 579 U/L. The patient had conservative 
primary surgery (left oophorectomy, omentectomy, 
and ascites fluid cytology). Midline incision performed, 
Durante operation evaluation with minimal uterus 
manipulation and seen solid mass 40 x 40 x 40 cm in 
size, rough surface, left ovary origin, omental attach 
then adhesiolysis done, rupture, and successfully 
removed. Internal abdominal organ evaluation: uterus 
corresponding 18-20 weeks GA, right and left 
Fallopian tube, right ovary, peritoneum, omentum, and 
liver normal. Histopathological concluded grade II 
immature teratoma of the left ovary with the 
neuroepithelial and fat immature component.  
 
Figure 1: Ultrasonography and Macroscopy of Immature Teratoma 
Durante Operation. A. Left adnexal mass hypohyperechoic with size 
that cannot reach by the probe at 19 weeks 5 day GA; B. Uterus 
size corresponding with 18-20 weeks GA, left Fallopian tube 
normal, post-oophorectomy; C. Lobulated solid mass with 
multiseptate cystic inside it. 
  
Patient management post-primary 
conservative surgery was contrasted MRI at 25 weeks 
3 day GA with the result there was no spreading. 
Chromosome analysis (amniocentesis) at 27 weeks 2 
day GA with the result the number of chromosome 46, 
XX, and not seem abnormality. It was decided to 
perform 4 cycles BEP chemotherapy administration, 
started at 27 weeks 2 day GA and stopped 2 weeks 
before labour (37 weeks 6 day GA) with regular 
fetomaternal USG evaluation (fetal scanning and fetal 
well being) every 2 weeks post chemotherapy, not 
found abnormality, and regular non stress test (NST) 
at GA > 34 weeks show reactive result. 
The pregnancy continued until at term; the 
female baby was born at 40 weeks 2 day GA, 2700 
gram, spontaneous pervaginam, APGAR score 7-8, 
not seen a congenital abnormality. Placental 
metastasis can occur even though it is very unlikely; 
the incidence has reported since 1866 just less than 
80 cases [2].
 
It will be better if the placenta is keep 
being evaluated pathologically, to exclude metastasis. 
The evidence of fetal metastasis has reported to date 
just 11 cases [2].
 
In this case, the placenta was 
seemed complete born, histopathological examination 
of the placenta and the amniotic membrane was 
performed, not seen immature teratoma cell invasion. 
The postpartum condition of the mother was good and 
followed up of the baby condition not found the sign of 
transient myelosuppression, IUGR (the baby born with 
weight 10%-25% at percentile), no congenital 
abnormality, no abdominal mass, and the level of AFP 
in the normal range.  
Supporting investigation at 1 week 
postpartum not found any signs of transient 
myelosuppression that is leucopenia (WBC count < 
5000/mm
3
), neutropenia (absolute neutrophil count < 
1500/mm
3
), anaemia, thrombocytopenia (PLT count < 
15.000/mm
3
). The baby has WBC count 17,230/mm
3
; 
hemoglobin 21.41 g/dL; Neutrophil 3,240/mm
3
; 
platelets 276,600/mm
3
. Alpha-fetoprotein of the 
patient > 5000 IU/mL which still in normal range 
(normal level for 2 weeks postpartum: 33.113 IU/mL), 
it is suggested for routine AFP follow up every month 
for 2 years. The patient was not suggested to 
breastfeeding at the chemotherapy period. The patient 
was not suggested to breastfeeding at the 
chemotherapy period. 
 
Figure 2: Histopathology of Left Ovarian Immature Teratoma and 
Atrophy of Right Ovary. A. Immature neuroepithelial component (40 
X magnification); B. Cortex contain primordial follicle depletion 
which some of it did not contain oocyte and blood vessels sclerosis 
(40X magnification); C. IHC ER-negative and D. IHC PR positive on 
neuroepithelial component (100 X magnification) 
 
Relaparotomy complete surgical staging 
including TAH, salpingectomy sinistra, SOD, 
lymphadenectomy pelvic bilateral and paraaortic, 
omentectomy, also peritoneal biopsy (bilateral 
paracolic-prevesical-Douglas cavity) performed at 58
th
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days postpartum. The result of histopathological 
examination there was no malignant cell and 
metastasis. 
The patient shows the psychological signs of 
POF including frightening and worry, irritability feeling, 
easy to mad, hard to concentrate, behaviour changes, 
depression, libido disturbance, and FSH level 50.01 
mU/L at post relaparotomy complete surgical staging. 
The result of histopathological examination of right 
ovary (contralateral) show ovarian atrophy. 
Immunohistochemistry to detect (estrogen receptor) 
ER and progesterone receptor (PR) were performed 
on left ovarian tumour (immature teratoma), with 
conclusion ER (-) and PR (+), so hormonal 
replacement therapy (HRT) can be given to managing 
POF signs with the possibility of tumour to relapse 
due to hormonal administration is low.  
 
 
Discussion 
 
The increasing of serum tumour marker 
during pregnancy often associated with the physiology 
of normal pregnancy. Tumour markers for diagnosis of 
the solid ovarian tumour are alpha-fetoprotein (AFP), 
CEA, LDH, CA19-9, and β-HCG. Immature teratoma 
often associated with the increasing of AFP and LDH 
[3]. Imaging for diagnosis of ovarian cancer including 
USG which have sensitivity 90%, specificity 87%, 
positive predictive value (PPV) 69% and negative 
predictive value (NPV) 97% in define of malignancy 
suspected ovarian mass [4]. Magnetic Resonance 
Imaging (MRI) performed if the diagnosis of USG is 
uncertain or to evaluate the spreading outside of the 
ovary. The using of MRI with contrast gadolinium-
based is saved during second and third trimester; it 
proved to have no mutagenic or teratogenic effects 
[5].
 
Alpha-fetoprotein is increased in part of a 
patient with pure immature teratoma which from 
embryogenic cells, but β-HCG is not increased [6]. In 
this patient the AFP level 699.9 IU/mL (normal level of 
AFP at second trimester 22-93 IU/mL), LDH: 579 U/L 
(normal level at second trimester: 240-480), CEA: 
12.43 ng/mL, CA 19-9 216 U/mL. During pregnancy, 
AFP is produced by the fetal yolk sac and then 
continued by the liver and gastrointestinal tract, the 
high level of AFP is suspected for the existence of 
neural defect abnormalities such as spina bifida, 
anencephaly, oesophageal defect, the failure of 
babies abdominal closing, and trisomy 21. 
Amniocentesis most accurate performed at 16 to 18 
weeks of gestational age [7], [8].
 
The patient had an 
amniocentesis at 27 weeks 2 days of gestational age 
for indication of the raising of AFP and searching 
congenital and also the chromosomal abnormality of 
the baby. If there is lethal anomaly abnormality, the 
pregnancy suggested being terminated. The result of 
amniocentesis analysis was not found chromosomal 
abnormality, the number chromosome was 46 with 
fetal sex chromosome XX and was not seen any 
major structural abnormality, and the result of fetal 
scanning ultrasonography after 22 weeks gestational 
age was not found major abnormality and the level of 
AFP gradually decrease after primary tumour removal 
until postpartum periods. The increasing of AFP level 
of the patient highly suspected from the primary 
tumour (germ cell). 
Estrogen and progesterone are increased 
during pregnancy. High level of estrogen receptor 
(ER) is often found in ovarian cancer cells. 
Meanwhile, a tumour with positive progesterone 
receptor (PR) has a higher survival rate compared 
with negative PR tumour [8].
 
The effects of ovarian cancer to pregnancy 
can be direct or indirect — the direct factor which 
affected directly such the metastasis to placenta and 
fetus. Metastasis to the placenta is very rare; it 
incidence since 1866 have reported less than 80 
cases and proved fetal metastasis until now just have 
been 11 cases [2].
 
The indirect effects are mediated 
by operative procedure and chemotherapy effects [3], 
[5], [8], [9].
  
 
Conservative Laparotomy Operation 
The side effect of surgery for the baby 
including exposure of anaesthetic agent, intrapartum 
and postpartum complication. The effect of 
anaesthetic agent administration that is hypoxia, 
hypotension, hypoglycemia, fever, pain, infection or 
thrombosis can cause serious side effects for the 
health of the baby. During surgery, it is necessary to 
minimalise the manipulation and retraction of the 
uterus to avoid decreasing of uteroplacental blood 
flow and separation of the placenta. Postpartum 
period needs adequate analgesic administration for 
pain can induce premature contraction [10].
 
The result of several studies, adnexal mass 
removal during pregnancy is safe enough for the 
mother and the baby [5]. The second trimester of 
pregnancy is ‘safety period’ or the best moment for 
performing surgery intervention of adnexal mass 
because at this period the dependency of hormonal 
secretion from corpus luteum during pregnancy is 
decreased so that the risk of spontaneous abortion is 
low [2], [5], [11].
 
There was a tocolytic administration 
consensus, the tocolytic agent can be given before or 
immediately after surgery and to be continued 24 to 
48-hour post-surgery [12].
 
Routine tocolytic 
administration still controversial, but the administration 
can be considered if there are signs of preterm labour 
[7], [13].
 
Tocolytic has benefit on ovarian tumour 
surgery, from 28 cases is proved that 86% of it had 
not found any uterine contraction and Mathevet, et. 
al., (2003) reported that 48 laparoscopy cases at first 
trimester (n = 17), second trimester (n = 27), and third 
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trimester (n = 4), tocolytic administration just for the 
indication of ovarian torsion, rupture of cyst, or 
persistent mass removal. The result showed minimal 
risk to the mother and the baby with the surgical 
technique and supporting expert experiences as 
consideration. On the cases without tocolytic before or 
after surgery was not found the signs of preterm 
labour postoperative. It is necessary to perform 
minimal manipulation of uterine to prevent contraction. 
Adnexal mass detected at trimester I or low 
malignancy suspected is managed by conservative 
(observation). But, septal mass, solid, papillary, 
nodular or persistent until 16 weeks of GA, surgery 
delay until trimester II (16-18 weeks GA) due to 
spontaneous abortion risk can reach 10%. Other 
surgery indications are acute abdomen: pain, rupture, 
and torsion [13]. Retrospective study show 
conservative management have high morbidity and 
mortality due to cystic fluid spill caused by 
spontaneous rupture [14], [15]. 
Corticosteroid administration for fetal lung 
maturation performed a minimum of 48 hours before 
the operation when it did at 24-34 weeks GA [7].
 
Adnexal mass detected after 35 weeks GA removed 
at the same time with section Caesarea [5]. 
Primary conservative surgery at an early 
stage is unilateral oophorectomy or cystectomy, 
omentectomy, and peritoneal fluid cytology. In 
advanced stage (II-IV), the pregnancy considered to 
be terminated before 24 weeks GA followed by 
adnexal mass removing and chemotherapy. If the 
advanced stage tumour found at more than 24 weeks 
GA, it just performed a biopsy, and following 
chemotherapy cytoreduction delay until labour [16], 
[17]. Relaparotomy complete surgical staging or 
cytoreduction performed after 3-6 weeks postpartum. 
 
Figure 3: Surgery Management Algorithm of Ovarian Cancer in 
Pregnancy [18]
 
 
Chemotherapy 
The Society of Obstetricians and 
Gynecologist Canada (SOGC) recommended 
chemotherapy at trimester II with the period of 
teratogenesis at organogenesis as consideration, so 
the best time is ≥ 12-14 weeks or trimester III (until 
35-37 weeks GA) [19]. Chemotherapy is given on the 
same dosage as a woman without pregnancy and it 
without significant side effects for the fetus [20]. 
Chemotherapy administration at trimester I raise 10-
20% the incidence of congenital malformation, fetal 
death, and spontaneous abortion [4], [5], [19].
 
Meanwhile, at trimester II and III, it raises the risk of 
IUGR (7%), low birth weight, preterm labour (5%), and 
stillbirth (5%). Chemotherapy after
 
35 weeks GA can 
raise the risk of neonatal neutropenia. At birth and first 
weeks of life can be found transient myelosuppression 
signs which can promote severe infection. At long 
term follow up can be found neurological development 
and psychological effects on the child.
 
The first choice chemotherapy combination 
for MOGCTs is 4 cycle every 3 weeks of bleomycin-
etoposide-cisplatin (BEP). Bleomycin-etoposide-
cisplatin has a recurrence-free survival rate of 84% 
[5]. The first side effects of BEP at trimester II: found 1 
case cerebral atrophy accompanied by 
ventriculomegaly, 4 cases polyhydramnios and IUGR, 
nephrotoxic suspected induced by cisplatin and 
neonatal alopecia [20]. The second, liver damage 
which caused decreasing synthesis of plasma 
procoagulant proteins and anticoagulant including 
fibrinopeptide A protein, fibrinolytic, factor VIII and 
thrombocyte activator that can be activated 
disseminated intravascular coagulation/DIC, 
thrombosis, and also bleeding. The third, indirectly 
destroy primordial follicle reserve, oocyte, and ovarian 
stroma caused premature ovarian failure (POF). 
Fertility profile of female BEP patients: primordial 
follicle decrease and stromal fibrosis in cortical 
atrophy with 42% of a patient developing POF [15].
 
Table 1: Cancer Therapy Choice Corresponding to Gestational 
Age [19]
 
 
 
The Mode of Delivery 
The optimal time to labour is after 35-37 
weeks and 3 weeks post-chemotherapy to avoid 
accumulation of chemotherapy and to allow recovery 
from possible bone marrow suppression of both 
mother and baby [8].
 
Mode of delivery preference was 
spontaneous vaginal delivery rather than a caesarean 
section. The benefits of spontaneous delivery are 
related to less blood loss, less operative risk and 
reduced infection risk. Mother under chemotherapy is 
not recommended to breastfeed due to several 
chemotherapy regimens excreted through breast milk 
which could result in neonatal pancytopenia [19].
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Prognosis 
A grade of immaturity predicted metastasis 
potency and prognosis. Five years survival rate is 
82%, 62%, and 30% for grade 1, 2, and 3 respectively 
in patients with grades 1, 2, and 3 treated with 
optimum chemotherapy, which it recurrence is 36% on 
6 years follow up, and 50% of patient succeed reach 
term pregnancy after performing primary surgical. The 
progressivity of patients performing complete surgical 
staging 8 % without delay the chemotherapy [3].
 
Long 
term outcome of a study done in Mexico on 84 
children who got affected by chemotherapy 
intrauterine due to their mother had cancer, not found 
congenital abnormality, development of neurology, 
cardiology, psychology and also disturbance in their 
marks at school [21]. 
In conclusion, the incidence of ovarian cancer 
in pregnancy is very rare. The choice of BEP 
chemotherapy, the time of operation and 
chemotherapy, regular follow up of fetal well-being will 
determine prognosis. Fetal outcome is good, but 
occur the signs of POF on the mother. Patients 
survival 62%, post-BEP free survival rate 84%, and 
progressivity post complete surgical staging 8% 
without delay chemotherapy. 
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